Klinische Studie NCT05949606 · Non-small Cell Lung Cancer

Klinische Studie NCT05949606 (Phase I/II) ist «aktiv (nicht rekrutierend)» auf ClinicalTrials.gov.

Erkrankung: Non-small Cell Lung Cancer · Registrierte Interventionen: SI-B001, SI-B003 · Erfasste Daten (Quelle): 2023-10-30, 2026-12, 2023-07-18, 2026-08-28.

Studienzusammenfassung (Quelle: ClinicalTrials.gov, Originaltext auf Englisch):

Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy of SI-B001+SI-B003 combination with or without chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer.

Quelle: https://clinicaltrials.gov/study/NCT05949606